SHUYINGLIUSHUYING LIU9004LIU, SHUYINGAssistant Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson25605252Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AMOncotargetFunctional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget. 2015 Feb 20; 6(5):2604-14.Oncotarget2015-02-20T00:00:002015Functional consequence of the MET-T1010I polymorphism in breast cancer.1901 East RoadHouston77054-3005TXAuthorship 1733785Authorship 1742694Authorship 1786685Authorship 1795903Authorship 1815211Authorship 1854214Authorship 1920242Authorship 1926718Authorship 1931382Authorship 196202212554733Hasegawa Y, Erickson JR, Goddard GJ, Yu S, Liu S, Cheng KW, Eder A, Bandoh K, Aoki J, Jarosz R, Schrier AD, Lynch KR, Mills GB, Fang XThe Journal of biological chemistryIdentification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J Biol Chem. 2003 Apr 04; 278(14):11962-9.J Biol Chem2003-01-27T00:00:002003Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor.14670967Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GBThe Journal of biological chemistryMechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem. 2004 Mar 05; 279(10):9653-61.J Biol Chem2003-12-11T00:00:002003Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells.17954226Murph M, Tanaka T, Pang J, Felix E, Liu S, Trost R, Godwin AK, Newman R, Mills GMethods in enzymologyLiquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol. 2007; 433:1-25.Methods Enzymol2007-01-01T00:00:002007Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis.19477432Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G, Coombes K, Muller W, Hung MC, Perou CM, Lee AV, Fang X, Mills GBCancer cellExpression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell. 2009 Jun 02; 15(6):539-50.Cancer Cell2009-06-02T00:00:002009Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases.23139263Gonzalez-Angulo AM, Liu S, Chen H, Chavez-Macgregor M, Sahin A, Hortobagyi GN, Mills GB, Do KA, Meric-Bernstam FAnnals of oncology : official journal of the European Society for Medical OncologyFunctional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy. Ann Oncol. 2013 Apr; 24(4):909-16.Ann Oncol2012-11-08T00:00:002012Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy.24296856Chavez-Macgregor M, Liu S, De Melo-Gagliato D, Chen H, Do KA, Pusztai L, Fraser Symmans W, Nair L, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AMCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyDifferences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev. 2014 Feb; 23(2):316-23.Cancer Epidemiol Biomarkers Prev2013-12-02T00:00:002013Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes.Breast Medical OncologyHealth Services ResearchInvestigational Cancer TherapeuticsLeukemiaMolecular & Cellular OncologySystems BiologyVeterinary Medicine & SurgeryMD AndersonMIEN-CHIEHUNGMIEN-CHIE HUNG8427HUNG, MIEN-CHIEProfessorJORGE ECORTESJORGE E CORTES8637CORTES, JORGE EProfessorNAOTO TUENONAOTO T UENO8465UENO, NAOTO TProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorGORDON BMILLSGORDON B MILLS8620MILLS, GORDON BProfessorFUNDAMERIC-BERNSTAMFUNDA MERIC-BERNSTAM8778MERIC-BERNSTAM, FUNDAProfessorMARIANACHAVEZ MAC GREGORMARIANA CHAVEZ MAC GREGOR9512CHAVEZ MAC GREGOR, MARIANAAssistant Professor1.027610.005495277research areas2.34170.016045740coauthor of39.0866.0447560similar to1140selected publicationsMIHAIGAGEA IURASCUMIHAI GAGEA IURASCU9472GAGEA IURASCU, MIHAIAssociate ProfessorAuthorship 2205064Authorship 2213671Authorship 2235943Authorship 2283571Authorship 2303045Authorship 231330312771940Luo RZ, Fang X, Marquez R, Liu SY, Mills GB, Liao WS, Yu Y, Bast RCOncogeneARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene. 2003 May 15; 22(19):2897-909.Oncogene2003-05-15T00:00:002003ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers.15466414Liu S, Yu S, Hasegawa Y, Lapushin R, Xu HJ, Woodgett JR, Mills GB, Fang XThe Journal of biological chemistryGlycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. J Biol Chem. 2004 Dec 03; 279(49):51075-81.J Biol Chem2004-10-01T00:00:002004Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase.17121877Murph M, Tanaka T, Liu S, Mills GBClinical cancer research : an official journal of the American Association for Cancer ResearchOf spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer. Clin Cancer Res. 2006 Nov 15; 12(22):6598-602.Clin Cancer Res2006-11-15T00:00:002006Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer.19855166Liu S, Murph M, Panupinthu N, Mills GBCell cycle (Georgetown, Tex.)ATX-LPA receptor axis in inflammation and cancer. Cell Cycle. 2009 Nov 15; 8(22):3695-701.Cell Cycle2009-11-15T00:00:002009ATX-LPA receptor axis in inflammation and cancer.21490305Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, Mills GB, Meric-Bernstam FMolecular cancer therapeuticsPI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther. 2011 Jun; 10(6):1093-101.Mol Cancer Ther2011-04-13T00:00:002011PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.22374333Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AMClinical cancer research : an official journal of the American Association for Cancer ResearchcMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 2012 Apr 15; 18(8):2269-77.Clin Cancer Res2012-02-28T00:00:002012cMET and phospho-cMET protein levels in breast cancers and survival outcomes.Authorship 2475065Authorship 2514391Authorship 2535378Authorship 2560903Authorship 257760316510595Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, Bast RC, Mills GB, Fang XCancer researchLysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res. 2006 Mar 01; 66(5):2740-8.Cancer Res2006-03-01T00:00:002006Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer.18367674Liu S, Fang X, Hall H, Yu S, Smith D, Lu Z, Fang D, Liu J, Stephens LC, Woodgett JR, Mills GBProceedings of the National Academy of Sciences of the United States of AmericaHomozygous deletion of glycogen synthase kinase 3beta bypasses senescence allowing Ras transformation of primary murine fibroblasts. Proc Natl Acad Sci U S A. 2008 Apr 01; 105(13):5248-53.Proc Natl Acad Sci U S A2008-03-26T00:00:002008Homozygous deletion of glycogen synthase kinase 3beta bypasses senescence allowing Ras transformation of primary murine fibroblasts.20215547Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A, Krishnamurthy S, Liu P, Yuan LX, Yamasaki F, Liu S, Hayashi N, Zhang D, Esteva FJ, Hortobagyi GN, Ueno NTClinical cancer research : an official journal of the American Association for Cancer ResearchPEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin Cancer Res. 2010 Mar 15; 16(6):1802-11.Clin Cancer Res2010-03-09T00:00:002010PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase.21233401Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam FClinical cancer research : an official journal of the American Association for Cancer ResearchIncidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011 Mar 01; 17(5):1082-9.Clin Cancer Res2011-01-13T00:00:002011Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.22235097Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, Mills GB, Meric-Bernstam F, Symmans WF, Pusztai LClinical cancer research : an official journal of the American Association for Cancer ResearchGene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res. 2012 Feb 15; 18(4):1109-19.Clin Cancer Res2012-01-10T00:00:002012Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer.Authorship 2683434Authorship 2701714Authorship 2702856Authorship 270976519001604Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GBJournal of the National Cancer InstituteLysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst. 2008 Nov 19; 100(22):1630-42.J Natl Cancer Inst2008-11-11T00:00:002008Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells.21324925Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, Gonz?lez-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, Kostler WJ, Lipton A, Bates M, Arteaga CLCancer researchTrastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 2011 Mar 01; 71(5):1871-82.Cancer Res2011-02-15T00:00:002011Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.21908557Fox EM, Miller TW, Balko JM, Kuba MG, S?nchez V, Smith RA, Liu S, Gonz?lez-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CLCancer researchA kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res. 2011 Nov 01; 71(21):6773-84.Cancer Res2011-09-09T00:00:002011A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.22474126Federico L, Ren H, Mueller PA, Wu T, Liu S, Popovic J, Blalock EM, Sunkara M, Ovaa H, Albers HM, Mills GB, Morris AJ, Smyth SSMolecular endocrinology (Baltimore, Md.)Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol Endocrinol. 2012 May; 26(5):786-97.Mol Endocrinol2012-04-03T00:00:002012Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice.Authorship 2735613Authorship 2745213Authorship 275260319139100Pamuklar Z, Federico L, Liu S, Umezu-Goto M, Dong A, Panchatcharam M, Fulkerson Z, Fulerson Z, Berdyshev E, Natarajan V, Fang X, van Meeteren LA, Moolenaar WH, Mills GB, Morris AJ, Smyth SSThe Journal of biological chemistryAutotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem. 2009 Mar 13; 284(11):7385-94.J Biol Chem2009-01-12T00:00:002009Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis.22179983Meng X, Zhong J, Liu S, Murray M, Gonzalez-Angulo AMCancer metastasis reviewsA new hypothesis for the cancer mechanism. Cancer Metastasis Rev. 2012 Jun; 31(1-2):247-68.Cancer Metastasis Rev2012-06-01T00:00:002012A new hypothesis for the cancer mechanism.23925999Sohn J, Do KA, Liu S, Chen H, Mills GB, Hortobagyi GN, Meric-Bernstam F, Gonzalez-Angulo AMAnnals of oncology : official journal of the European Society for Medical OncologyFunctional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy. Ann Oncol. 2013 Oct; 24(10):2522-2526.Ann Oncol2013-08-07T00:00:002013Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy.24669015Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam FAnnals of oncology : official journal of the European Society for Medical OncologyOpen-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7.Ann Oncol2014-03-24T00:00:002014Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?.24979294Liu S, Meng X, Chen H, Liu W, Miller T, Murph M, Lu Y, Zhang F, Gagea M, Arteaga CL, Mills GB, Meric-Bernstam F, Gonz?lez-Angulo AMOncotargetTargeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget. 2014 Oct 15; 5(19):9049-64.Oncotarget2014-10-15T00:00:002014Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.25454687Parinyanitikul N, Lei X, Chavez-MacGregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AMClinical breast cancerReceptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. Clin Breast Cancer. 2015 Apr; 15(2):153-60.Clin Breast Cancer2014-10-02T00:00:002014Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes.74Professor10Assistant Professor14Associate ProfessorAuthorship 3740834Authorship 3740871Authorship 3740881Authorship 3740893Authorship 842002Authorship 842061Authorship 843875Authorship 850065Authorship 854436Authorship 857484Authorship 860056Journal of Biological ChemistryErratum. Journal of Biological Chemistry. 284:21100.ErratumJournal of CancerEffects of CDK4/6 inhibition in hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer cells with acquired resistance to paclitaxel. Journal of Cancer. 7:947-956.Effects of CDK4/6 inhibition in hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer cells with acquired resistance to paclitaxelPLoS OneThe association between EGFR and cMET expression and phosphorylation and its prognostic implication in patients with breast cancer. PLoS One. 11.The association between EGFR and cMET expression and phosphorylation and its prognostic implication in patients with breast cancerJournal of Cellular BiochemistryErratum. Journal of Cellular Biochemistry. 93:427.ErratumOncogeneP-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. Oncogene. P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancerNatureComprehensive molecular portraits of human breast tumours. Nature. 490:61-70.Comprehensive molecular portraits of human breast tumoursJournal of CancercMET activation and EGFR-directed therapy resistance in triple-negative breast cancer. Journal of Cancer. 5:745-753.cMET activation and EGFR-directed therapy resistance in triple-negative breast cancer15258897Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, Hasegawa Y, Lu Y, Trost R, Bevers T, Jonasch E, Aldape K, Liu J, James RD, Ferguson CG, Xu Y, Prestwich GD, Mills GBJournal of cellular biochemistryLysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem. 2004 Aug 15; 92(6):1115-40.J Cell Biochem2004-08-15T00:00:002004Lysophosphatidic acid production and action: validated targets in cancer?D008246Chemicals & Drugs471470.922224LysophospholipidsD049368Chemicals & Drugs29800.964225Receptors, Lysophosphatidic AcidD011755Chemicals & Drugs30510.966884PyrophosphatasesD019859Chemicals & Drugs2114190.767054Proto-Oncogene Proteins c-metD043264Chemicals & Drugs8200.988236Phosphodiesterase IAuthorship 936716130518672Liu S, Li S, Wang B, Liu W, Gagea M, Chen H, Sohn J, Parinyanitikul N, Primeau T, Do KA, Vande Woude GF, Mendelsohn J, Ueno NT, Mills GB, Tripathy D, Gonzalez-Angulo AMMolecular cancer therapeuticsCooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer. Mol Cancer Ther. 2019 02; 18(2):399-412.Mol Cancer Ther2018-12-05T00:00:002018Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professor17611702Estrella VC, Eder AM, Liu S, Pustilnik TB, Tabassam FH, Claret FX, Gallick GE, Mills GB, Wiener JRInternational journal of oncologyLysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. Int J Oncol. 2007 Aug; 31(2):441-9.Int J Oncol2007-08-01T00:00:002007Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway.23708659Wu CF, Liu S, Lee YC, Wang R, Sun S, Yin F, Bornmann WG, Yu-Lee LY, Gallick GE, Zhang W, Lin SH, Kuang JOncogeneRSK promotes G2/M transition through activating phosphorylation of Cdc25A and Cdc25B. Oncogene. 2014 May 01; 33(18):2385-94.Oncogene2013-05-27T00:00:002013RSK promotes G2/M transition through activating phosphorylation of Cdc25A and Cdc25B.24055055Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, Harrison M, Mooney T, McMichael JF, Luo J, Tao Y, Goncalves R, Schlosberg C, Hiken JF, Saied L, Sanchez C, Giuntoli T, Bumb C, Cooper C, Kitchens RT, Lin A, Phommaly C, Davies SR, Zhang J, Kavuri MS, McEachern D, Dong YY, Ma C, Pluard T, Naughton M, Bose R, Suresh R, McDowell R, Michel L, Aft R, Gillanders W, DeSchryver K, Wilson RK, Wang S, Mills GB, Gonzalez-Angulo A, Edwards JR, Maher C, Perou CM, Mardis ER, Ellis MJCell reportsEndocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013 Sep 26; 4(6):1116-30.Cell Rep2013-09-19T00:00:002013Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.